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Abstract
The only currently available vaccine against tuberculosis (TB) is Mycobacterium bovis Bacille Calmette-Guerin (BCG),
which has inconsistent efficacy to protect against the disease in adults. M. tuberculosis (MTB) cell wall components
have been implicated in the pathogenicity of TB and therefore have been a prime target for the identification and
characterization of cell wall proteins with potential application in vaccine development. In this regard,
proteoliposomes (PLs) derived from mycobacteria containing lipids and cell wall proteins could be potential
vaccine candidates against TB. In the present study PLs derived from BCG were prepared. These homogeneous
population of spherical microparticles was then immunized into Balb/c mice. Sera of immunized animals showed
high IgG response and strong cross-reactivity against different MTB antigens.These results showed that BCG PLs
could be potential vaccine candidates against TB.
Introduction
TB remains a major infectious disease which causes high
morbidity and mortality worldwide [1]. BCG, an attenu-
ated strain of Mycobacterium bovis (Mb), is the current
vaccine approved for human use against TB. It is most
effective in protecting children from the disease; while its
efficacy in adults is poor especially against pulmonary TB,
proving the prevailing necessity to obtain a more effective
vaccine [2].
The availability of the complete genome sequence of
MTB and Mb, as well as access to different programs for
epitope prediction and homology search between
sequences, allows the identification of conserved proteins
among both species with the potential of identifying com-
ponents for new vaccines [3]. Additionally, many studies
support the role of mycobacterial cell wall components in
the development of TB pathogenesis [4].
Since mycobacterial cell wall components have been sug-
gested to be potential targets for the development of new
TB vaccine formulations, we attempted to use PLs from
BCG to determine the immunogenicity and cross-reactivity
of these microparticles against MTB. The presence of pro-




Proteins with possible localization in the cell wall of MTB
were retrieved from the scientific literature. From a total of
306 MTB cell wall proteins a set of five immunodominant
and immunogenic proteins (Acr, Ag85B, Mce1A, HbhA
and L7/L12) were selected for in silico alignment with the
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Prediction of B cell epitopes of these proteins was per-
formed by using ABCpred server (http://www.imtech.
res.in/raghava/abcpred/). Selected B cell epitopes were
synthesized in the Centre for Genetic Engineering and
Biotechnology (CIGB), Cuba, and were used in the
immunogenicity assay.
Preparation and partial characterization of PLs derived
from Mb BCG (BCG PLs)
BCG PLs were prepared according to the methodology
described by Rodriguez et al [5]. Molecular size of PLs was
determined by size exclusion chromatography using an
XK 16/100 column packed with Sephacryl S-1000 (Phar-
macia). The morphology of BCG PLs was determined by
Transmission Electron Microscopy (TEM) with negative
staining.
Immunogenicity and cross-reactivity assays
Eighteen male Balb/c mice (5-6 weeks), supplied by the
School of Health Sciences (Universiti Sains Malaysia,
Malaysia) were used in the experiments. All procedures
were carried out according to the international regulations
of laboratory animal experimentation [6] and approved by
the USM Animal Ethics Committee.
Three groups of animals (n=6 per group) were inocu-
lated with either 100 µl PBS (negative control), BCG (106
CFU) or BCG PLs (50 mg + Freund’s Incomplete Adju-
vant) by the intraperitoneal route. Mice were immunized
at days zero and 21 and bled for serum collection at days
zero, 14, 28 and 35. Sera samples from each group were
stored at -20 °C for subsequent analysis.
Humoral immune response and cross-reactivity against
MTB were evaluated by indirect ELISA [5]. Coating anti-
gens comprised BCG whole cells (106 CFU/mL), five B
cell epitopes from MTB proteins or MTB antigens such
as cell wall fraction (CWF), soluble cell wall proteins
(SCWP), lipoarabinomanan (LAM) and purified protein
derivative (PPD). These antigens were kindly provided by
BEI Resources, ATCC, USA.
Statistical analysis
Data from the in vitro assays were analyzed for statistical
significance using a simple ANOVA test. Duncan’s multi-
ple range test and Tukey’s Post Hoc Test were used for
the determination of pairs with significant differences.
Results and discussion
In silico assays
MTB cell wall proteins have been suggested to contain
virulence factors [4]. Since the BCG genome is more
than 90% homologous to that of MTB [7], it is reasonable
to assume that BCG PLs can be potential vaccine candi-
dates against TB.
The five MTB cell wall proteins selected in our study are
100% identical to their corresponding proteins in BCG
(data not shown). This could explain the partial protection
afforded by BCG vaccination in humans [8].
Preparation and partial characterization of BCG PLs
The molecular size of BCG PLs was estimated by the coef-
ficient of Ve/Vt relation obtained from size exclusion
chromatography. This coefficient was 0.45, indicating that
the molecular size of PLs was above 100 nm, using as
reference the characterization studies of VAMENGOC-BC
vaccine and V. cholerae PLs [9,10]. The morphology of
BCG PLs as assessed by TEM showed a homogeneous
population of spherical structures (results not shown). The
molecular size of BCG PLs was also confirmed by TEM.
Immunogenicity study
There were no statistically significant differences among
groups of mice immunized with BCG PLs or BCG. How-
ever both groups induced significantly (p<0.05) higher
IgG levels against BCG whole cells than those inoculated
with PBS (Fig. 1A).
In addition, animals immunized with BCG PLs produced
significantly (p<0.05) higher IgG levels against B cell
epitopes compared to those from animals inoculated with
PBS (Fig. 1B).
Proteoliposomes from bacteria contain LPS, proteins and
other molecules that are known as pathogen-associated
molecular patterns (PAMPs), which possess immune
enhancing, and modulator effects [9]. The interaction
between cell wall proteins, lipids and detergent molecules
leads to the extraction and formation of spherical nanopar-
ticles or proteoliposomes [9]. Our results suggest the pre-
sence of the five B cell epitopes from MTB in the BCG PLs
(Fig.1B). The epitopes identified in silico belong to proteins,
which are involved in the pathogenicity of MTB. Therefore,
these antigens could be used to stimulate a protective
response against TB.
For example, the Acr protein is a major MTB antigen
recognized by the sera of a high proportion of TB patients
[11]. Recognition of B cell epitope of Ag85B may have sig-
nificance for protection as this protein is related to the
interaction with fibronectin, a key element of the invasion
of tissues by MTB [12]. Moreover, Mce1A protein plays
an important role in macrophage invasion [13], so
Mce1A-antibodies could affect the entry of mycobacteria
into the cell. HbhA protein is involved in extrapulmonary
dissemination of MTB [14]. Immune response against
these B cell epitopes could prevent the development of
extrapulmonaryTB.
Cross-reactivity study
Sera from mice immunized with BCG PLs showed specific
IgG response against all MTB antigens used (Fig. 2). This
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response was significantly (p<0.01) higher compared to
animals inoculated with PBS. The induction of specific
humoral immune response recognizing MTB antigens
after the immunization with BCG PLs is interesting
considering the potential role of antibodies in the protec-
tion against TB [1]. In addition, this result demonstrates
the presence of other relevant MTB antigens in BCG PLs,
which could be involved in inducing cross-protective
immunity against TB.
Conclusions
In this paper we selected in silico a group of MTB cell wall
proteins which posses 100% identity with its counterparts
in Mb BCG. These proteins were positively recognised by
sera of mice immunized with BCG PLs obtained by deter-
gent extraction method. This result suggests that BCG PLs
contain the highly conserved proteins, which also induce a
strong humoral immune response and could generate a
cross-protective response to MTB infection.
Figure 1 Antigen recognition and cross reactivity induced by BCG PLs immunization. ELISA. A Reactivity of total IgG from mice
immunized with BCG PLs or BCG to BCG antigens (whole cells). B Reactivity of total IgG from mice immunized with BCG PLs against B epitopes
from MTB. The statistical analysis was performed by one-way ANOVA followed by Tukey post-hoc test. (*) significant differences with respect to
NC group, p < 0.05
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